AIR: No Impact of Switching From 3-Drug to 2-Drug ART on Adverse Disease Outcomes in Virologically-Suppressed Persons With HIV

July 6-10, 2020; Virtual
Switching to 2-drug ART did not increase risk of virologic suppression, serious non-AIDS events, or death in virologically suppressed persons with HIV.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

From Dr. Fidelia Bernice and Clinical Care Options (CCO), expert commentary on managing polypharmacy in people with HIV

Fidelia Bernice, PharmD Released: January 6, 2022

Expert faculty discuss guideline recommendations for individualizing ART, from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD
Program Director
Jean-Michel Molina, MD, PhD Cristina Mussini, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: December 29, 2021 Expired: December 28, 2022

Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in patients with suppressed HIV-1 RNA, particularly if preexisting resistance is suspected

John D. Baxter, MD Released: December 29, 2021

From Dr Gregory Huhn and Clinical Care Options (CCO), slides on new data from fall 2021 HIV conferences expand our understanding of adverse events with specific ART regimens

Released: December 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings